For decades, we’ve accepted that damaged brain tissue cannot regenerate — that once neurons die, they’re gone for good.

It’s why strokes can leave permanent disabilities, and why Alzheimer’s disease remains incurable. But, emerging research into neural stem cells (NSCs) is beginning to challenge that belief and provide hope: could we one day cure the incurable?

Neurodegenerative diseases are among the leading causes of death worldwide, particularly in low- and middle-income countries. With their prevalence expected to double every two decades, the demand for more effective treatments continues to grow.

The absence of any true cure makes the promise of stem cell therapy feel like a shift from speculative science toward tangible clinical reality.

Neural stem cells (NSCs) are a unique population of self-renewing; multipotent cells found within the nervous system. They can differentiate into the brain’s three main cell types (neurons, astrocytes, and oligodendrocytes) and are responsible for building the nervous system during development.

Scientists previously believed that neurogenesis – the process of forming new neurons – stopped after birth.

However, we now know that small populations of NSCs persist into the adult brain, helping to repair minor damage and promote neuroplasticity.

This serves as a reminder that science is never static, and that what we accept as fact can change as our understanding deepens.

Today, scientists are racing to unlock the full potential of NSCs by pushing boundaries towards successfully repairing major neurological damage.

In 2023, a research trial investigating intranasal NSC administration for treating patients with cerebral palsy showed huge promise.

Motor function and daily activity scores both improved for the participants, and, unlike intrathecal and intravenous delivery, they showed no major adverse effects.

Biomarker and imaging data showed how the transplanted NSCs directly contributed to improved brain connectivity and neuroplasticity.

Despite the trial including a limited number of patients, the findings mark a significant step forward in improving delivery methods and characterising the safety profile of NSC therapy.

The ability of NSCs to promote neuroplasticity was highlighted again in 2024, when research showed that NSCs could allow the brain to reorganise and replace lost neurons in Alzheimer’s disease, Parkinson’s disease, and stoke sufferers.

Instead of treating symptoms, they treat the cause.

In Alzheimer’s disease particularly, where neurons are progressively destroyed, the potential of NSC-based medicine is profound, bringing new hope for the future of neurodegenerative disease treatment.

Despite rapid and ever-evolving scientific progress, rewiring a brain is far from simple. Researchers are still uncovering how transplanted NSCs communicate with host neurons and integrate into neural circuits.

As this avenue of neuroscience is relatively new, long-term studies are limited, with many questions about stability and long-term efficacy currently left unanswered.

Through their self-renewal and proliferative properties – the qualities that make NSCs so powerful in medicine – NSCs also present risks. Both human and animal studies have shown that many years after SC transplantation, transplanted-NSC-derived tumours can arise.

While cell engineering and delivery advances have significantly reduced this risk, it remains a sobering reminder of the double-edged nature of cellular therapies.

They are capable of both extraordinary healing, and unintentional harm.

There is a long road ahead, but the clinical translation of NSCs currently signify hope for the future of neurodegenerative disease treatment.

Disease and damage to our brains may not be as permanent as we once thought.

Image Credit: Unsplash